Skip to main content

Table 1 Characteristics of the study population

From: Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer

 

Study cohort (n = 99)

Age (years) (mean (median:IQR))

65.9 (66 : 62.0-69.0)

PSA (ng/mL) (mean (median:IQR))

46.1 (7.4 : 5.5-11.6)a

Family history of PCa (no-yes-NA)

43.4%-13.1%-42.4%

First biopsy (n (%))

91 (92.0%)

Prostate volume (mean (median:IQR))

55.5 (49: 36-72)

PSA density (ng/mL x cc-1) (mean (median : IQR))

0.89 (0.15 : 0.09-0.27)

DRE (abnormal) (%)

54 (54.5%)

PCa diagnosis (n (%))

54 (54.5%)

 Gleason score ≤6 (n (%))

17 (31.5%)

 Gleason score 7 (n (%))

18 (33.3%)

 Gleason score 8-10 (n (%))

19 (35.2%)

  1. DRE digital rectal examination, IQR inter quartile range, NA not applicable, PCa prostate cancer, PSA prostate-specific antigen
  2. aFour men had serum PSA values of more than 100 ng/mL. Without these outliers the average PSA value was 12.1 ng/mL